NLRC4 and amyotrophic lateral sclerosis: While selective inflammasome inhibition is a promising therapeutic approach in monogenic autoinflammatory syndromes associated with NLRP3- or NLRC4-activating mutations (27), we hypothesize that strategies that impact multiple inflammasome pathways may hold more promise in CNS disorders like ALS where multiple inflammasomes are dysregulated (28).